[Falls Church, Virginia, December 20th, 2022] Magna Labs is proud to announce that we’ve been selected as an inaugural member of the Merck Digital Sciences Studio (MDSS). This prestigious accelerator program is a collaboration between Merck, Microsoft for Startups, and the New Jersey Innovation Institute (NJII). It is supported by investments from Merck Global Health Innovation Fund LLC, Northpond Ventures, and McKesson Ventures.
This opportunity allows us to bring our low-code bioinformatics testing and benchmarking software into the biopharma sector, helping drive quality in computational innovation from the earliest stages of research and drug discovery through to diagnostics and therapeutic selection. High-quality, well-validated bioinformatics software ensures that scientists and patients alike achieve better outcomes more quickly. We are grateful to the MDSS team for supporting our mission to enhance precision in precision medicine.
The MDSS is a 10-month startup accelerator designed to foster the development of innovative digital technologies for drug discovery and development. It combines the expertise of Merck, Microsoft for Startups, and NJII, a subsidiary of the New Jersey Institute of Technology (NJIT). Participating startups receive direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures.
The program offers members access to hands-on mentorship, connections with industry-leading partners, and entrepreneurial training. Participants also benefit from workshops, coaching, subsidized office space, and access to Microsoft's Founders Hub resources, including Azure Cloud computing credits.
Based in Newark, New Jersey, and Cambridge, Massachusetts, this collaborative cohort focuses on pioneering biotechnical approaches, particularly in artificial intelligence (AI) and machine learning (ML). Leveraging the expertise and tools provided by clinical scientists, the MDSS program aligns with Merck’s mission to strengthen the life sciences ecosystem.
Magna Labs is a pioneering bioinformatics company focused on automating quality assurance (QA) processes for genomic and computational biology research. Its no-code platform, Miqa, empowers researchers and bioinformaticians to validate software pipelines with greater ease, efficiency, and accuracy, ensuring reproducibility and compliance in data-driven science. Magna Labs is committed to advancing innovation and standardization in bioinformatics and precision medicine.
